|
| |
| Cat. No |
Model |
Description |
Unit |
Price
(VAT별도) |
납기 |
재고 |
DataSheet |
주문/견적 |
| LCA-23-319740 |
NB110-55629 |
ABCB9 Antibody//Human/Rabbit |
1/EA |
|
|
|
|
문의 |
|
|
|
|
|
|
|
Subject
|
ABCB9 Antibody |
|
Description
|
/ Human/Rabbit |
|
Clonality
|
Poly |
|
Company
|
Novus biologicals |
|
Application
|
IHC-P, IHC-P |
|
Conjugation
|
|
|
Immunogen
|
|
|
Contents
|
Description:Summary: | Species: | Hu | | Applications: | IHC-P, IHC | | Clonality: | Polyclonal | | | Gene: | ABCB9 | | Purity: | peptide affinity purified | | Host: | Rabbit | | | Specificity: | This is specific to the human Mdr/Tap protein. | Details: | Immunogen: | Synthetic peptide - KLH conjugated. | | Epitope: | Cytoplasmic domain of huma n | Gene Symbol: ABCB9 | Entrez: | 23457 (Human) | | Related Genes: | TAP1, TAP2, SEC14L2, SEC14L3, DHFR, ABCB8, ABCB6, MDM4, PADI1, NDUFA2, MED23, ABCA4, CD14, MSH3, ABCB10, PDIA2, ABCC9, P4HB, ABCC1, TRG, SGMS1, HSD17B4, PROC, CLEC5A, APC, ABCA1, ABCB4, ITGB2, ABCB1, ABCB7, ABCB11, ABCD1, SP1, ITGAM, ABCG8, ABCG5, ABCC6, HLA-E, LAMP1, PSG1 | Background: Abcb1/MDR1/P glycoprotein is an ATP dependent transporter that mediates efflux of chemotherapeutic agents from the intracellular milieu. It has also been associated with volume-regulated chloride channel activity and basal to apical transendothelial migration of mononuclear phagocytes. Species: | Reactivity: | Cross reacts with Human. | Applications: | Uses: | Immunohistochemistry - Paraffin | | Dilutions: | immunohistochemistry 2.5 ug/ml, Immunohistochemistry-Paraffin 2.5 ug/ml | | Concentrations: | 1.0 mg/ml | Packaging: | Buffer: | Phosphate buffered saline, PH 7.7 | | Storage: | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | | Preservative: | 0.01% Sodium Azide | | Limitations: | This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months. | |
|
|
|
|
